Developing new treatments for antibiotic-resistant infections and emerging diseases
Development of Therapeutic Products for Biodefense, AntiMicrobial Resistant (AMR) Infections and Emerging Infectious Diseases
This study is working on new treatments to help people with infections that don't respond to regular antibiotics, so if you're struggling with tough-to-treat bacteria, this research could lead to better options for you in the future.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Crestone, INC. NIH-funded |
| Lab location | 1 site (Boulder, United States) |
| Project ID | NIH-11161135 on NIH RePORTER |
What this research studies
This research focuses on creating new therapeutic products to combat antibiotic-resistant infections and emerging infectious diseases. It involves a series of development activities, including optimizing drug candidates, conducting preclinical studies, and assessing safety and efficacy in clinical trials. Patients may benefit from innovative treatments that target resistant bacteria, particularly those that are difficult to treat with existing medications. The research aims to advance these products through rigorous testing and regulatory processes.
Who could benefit from this research
Good fit: Ideal candidates for participation or benefit are individuals with infections caused by antibiotic-resistant bacteria or those at risk of emerging infectious diseases.
Not a fit: Patients with infections that are not caused by antibiotic-resistant bacteria or those who do not have emerging infectious diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to effective new treatments for patients suffering from antibiotic-resistant infections.
How similar studies have performed: Previous research has shown promise in developing treatments for antibiotic-resistant infections, indicating that this approach has potential for success.
Where this research is happening
Boulder, United States
- Crestone, INC. — Boulder, United States (Active)
Researchers
- Principal investigator: Oschner, Urs — Crestone, INC.
- Study coordinator: Oschner, Urs
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.